Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Sticks To Its Guns: Amyvid Alzheimer’s Screening Not Covered In Medicare Population

This article was originally published in RPM Report

Executive Summary

The final coverage decision for Lilly’s Amyvid sticks with the proposal to limit payment to use in clinical trials. That is a setback for Lilly, but reinforces the Medicare agency’s commitment to the Coverage with Evidence Development pathway.

You may also be interested in...



Alzheimer’s Biomarker Development Hampered By ‘Limited’ Commercial Incentives

Eli Lilly executive suggests the public sector may need to come up with a solution to drive innovation if the private sector does not do so.

FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns

Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.

CMS Coverage Group Changes Management, But Not Priorities

Director of CMS’ Coverage and Analysis Group Louis Jacques will leave the agency in March; his replacement, Deputy Tamara Syrek Jensen, will continue to make Coverage with Evidence Development a top priority.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS081060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel